单抗制备的过程模拟和经济性分析

doi:10.11949/j.issn.0438-1157.20171645

化工学报 ›› 2018, Vol. 69 ›› Issue (7): 3198-3207.DOI: 10.11949/j.issn.0438-1157.20171645

单抗制备的过程模拟和经济性分析

史策¹, 虞骥^1,2, 高栋², 王海彬², 姚善泾¹, 林东强¹

1 浙江大学化学工程与生物工程学院, 生物质化工教育部重点实验室, 浙江杭州 310027;
2 浙江海正药业股份有限公司, 浙江台州 318000

收稿日期:2017-12-14 修回日期:2018-01-18 出版日期:2018-07-05 发布日期:2018-07-05
通讯作者: 林东强
基金资助:
国际科技合作专项（2015DFG42070）；国家自然科学基金项目（21476198，21576233，21776243）。

Process simulation and economic evaluation of monoclonal antibody production

SHI Ce¹, YU Ji^1,2, GAO Dong², WANG Haibin², YAO Shanjing¹, LIN Dongqiang¹

1 Key Laboratory of Biomass Chemical Engineering of Ministry of Education, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, Zhejiang, China;
2 Zhejiang Hisun Pharmaceutical Co., Ltd., Taizhou 318000, Zhejiang, China

Received:2017-12-14 Revised:2018-01-18 Online:2018-07-05 Published:2018-07-05
Supported by:
supported by the International Science & Technology Cooperation Program of China (2015DFG42070) and the National Natural Science Foundation of China (21476198, 21576233, 21776243).

摘要/Abstract

摘要：

单克隆抗体（简称单抗）是最重要的生物技术药物，随着产业规模的持续扩大和同行竞争的不断加剧，制备流程的合理性和过程经济性越来越受到重视。本文采用生物过程模拟软件SuperPro Designer分别建立了500、2000、5000和15000 L四个培养规模的单抗制备流程，通过过程分析和成本核算，确定经济热点并提出相应的优化策略。结果表明，单抗制备的规模效应明显，随着规模扩大，生产成本显著降低，经济热点从设备相关成本转移到原材料和消耗品，主要包括无血清培养基和蛋白A亲和层析介质。上游优化的关键是提高细胞的单抗表达量，当表达量达到5 g/L以上时，对成本影响减弱，转为下游过程控制；下游优化的重点在于蛋白A亲和层析介质，包括载量、价格和循环使用次数；整体优化可利用交错模式，采用三个主生物反应器配置一条下游生产线，其中生产规模和设备成本是关键。研究表明，通过合理的过程模拟和经济评价，可以充分了解单抗制备过程的关键热点，提出合适的优化策略，提高生产效率，降低制备成本。

关键词: 单克隆抗体, 过程模拟, 经济评价, 热点分析, 过程优化

Abstract:

Monoclonal antibody (mAb) is the most important biopharmaceuticals. With the continuous expansion of industrial-scale production and competition, the process rationality and economy have attracted more and more attention. In this paper, four scales of mAb manufacturing processes of 500, 2000, 5000 and 15000 L were established by using SuperPro Designer software, a bioprocess simulation software. Through the process analysis and cost evaluation, the economic 'hotspots' were determined and the optimization strategies were then proposed. The results showed that the scale effect on the production cost was obvious. With the increase of production scale, the cost would be significantly reduced, and the economic hotspots were transferred from equipment-dependent costs to raw materials and consumables, including serum-free medium and Protein A affinity resin. The key for upstream optimization was to increase the titer of mAb expression during cell culture. But when the titer was higher than 5 g/L, the effect of titer increasing on the cost was weakened and the cost was then mainly controlled by downstream process. The downstream optimization should focus on Protein A affinity resins, including capacity,price and the reuse cycles. The optimization of overall process would be the stagger mode with three main bioreactors corresponding one downstream line, for which the production scale and equipment cost were two key factors. The results demonstrated that with the aid of reasonable process simulation and economic evaluation, some hotspots of manufacture process could be identified and the appropriate optimization strategies would be proposed to improve the process efficiency and reduce the production cost.

Key words: monoclonal antibody, process simulation, economic evaluation, hotspots analysis, process optimization

中图分类号:

TQ018

史策, 虞骥, 高栋, 王海彬, 姚善泾, 林东强. 单抗制备的过程模拟和经济性分析[J]. 化工学报, 2018, 69(7): 3198-3207.

SHI Ce, YU Ji, GAO Dong, WANG Haibin, YAO Shanjing, LIN Dongqiang. Process simulation and economic evaluation of monoclonal antibody production[J]. CIESC Journal, 2018, 69(7): 3198-3207.

参考文献 33

[1]	WEINER L M, SURANA R, WANG S. Antibodies and cancer therapy:versatile platforms for cancer immunotherapy[J]. Nature Reviews Immunology, 2010, 10(5):317-327.
[2]	BECK A, WURCH T. 6th annual European antibody congress 2010[J]. MAbs, 2011, 3(2):111-132.
[3]	ECKER D M, JONES S D, LEVINE H L. The therapeutic monoclonal antibody market[J]. MAbs, 2015, 7(1):9-14.
[4]	RODGERS K R, CHOU R C. Therapeutic monoclonal antibodies and derivatives:historical perspectives and future directions[J]. Biotechnology Advances, 2016, 34(6):1149-1158.
[5]	CHAPMAN K, ADJEI A, BALDRICK P, et al. Waiving in vivo studies for monoclonal antibody biosimilar development:national and global challenges[J]. MAbs, 2016, 8(3):427-435.
[6]	GAO K, WANG J. The biopharmaceutical industry in China:history and future perspectives[J]. Frontiers of Medicine, 2012, 6(2):101-111.
[7]	李敏, 吴日伟. 国内外单抗药物市场概述[J]. 中国生物工程杂志, 2017, 37(3):106-114. LI M, WU R W. The market overview of monoclonal antibodies in both domestic and abroad[J]. Journal of Chinese Biotechnology, 2017, 37(3):106-114.
[8]	SHUKLA A A, HUBBARD B, TRESSEL T, et al. Downstream processing of monoclonal antibodies-application of platform approaches[J]. Journal of Chromatography B Analytical Technologies in the Biomedical & Life Sciences, 2007, 848(1):28-39.
[9]	KELLEY B. Industrialization of mAb production technology:the bioprocessing industry at a crossroads[J]. MAbs, 2009, 1(5):443-452.
[10]	PAPAVASILEIOU V, KOULOURIS A, SILETTI C, et al. Optimize manufacturing of pharmaceutical products with process simulation and production scheduling tools[J]. Chemical Engineering Research & Design, 2007, 85(7):1086-1097.
[11]	殷绚, 杨小健, 李荣雨, 等. 连续发酵生产乙醇的过程模拟与优化研究[J]. 高校化学工程学报, 2010, 24(1):176-181. YIN X, YANG X J, LI R Y, et al. Simulation and optimization of continuous ethanol fermentation process[J]. Journal of Chemical Engineering of Chinese Universities, 2010, 24(1):176-181.
[12]	SILVA A N D, PEREZ R, MINIM V P R, et al. Integrated production of whey protein concentrate and lactose derivatives:What is the best combination?[J]. Food Research International, 2015, 73:62-74.
[13]	TORRES-ACOSTA M A, AGUILAR-YÁÑEZ J M, RITOALOMARES M, et al. Economic analysis of Uricase production under uncertainty:contrast of chromatographic purification and aqueous twophase extraction (with and without PEG recycle)[J]. Biotechnology Progress, 2016, 32(1):126-133.
[14]	ROUF S A, DOUGLAS P L, MOO-YOUNG M, et al. Computer simulation for large scale bioprocess design[J]. Biochemical Engineering Journal, 2001, 8(3):229-234.
[15]	PAPAVASILEIOU V, SILETTI C, PETRIDES D. Systematic evaluation of single-use systems using process simulation tools[J]. Biopharm International, 2008, 21(Suppl.):16-29.
[16]	NANDI S, KWONG A T, HOLTZ B R, et al. Techno-economic analysis of a transient plant-based platform for monoclonal antibody production[J]. MAbs, 2016, 8(8):1456-1466.
[17]	IDRIS A, CHUA G K, OTHMAN M R. Incorporating potential environmental impact from water for injection in environmental assessment of monoclonal antibody production[J]. Chemical Engineering Research & Design, 2016, 109:430-442.
[18]	FAHRNER R L, KNUDSEN H L, BASEY C D, et al. Industrial purification of pharmaceutical antibodies:development, operation, and validation of chromatography processes[J]. Biotechnology & Genetic Engineering Reviews, 2001, 18(1):301-327.
[19]	埃尔马·海因茨勒, 阿尔诺·比韦尔, 查尔斯·库尼. 可持续发展的生物过程[M]. 林东强, 姚善泾, 梅乐和, 译. 北京:化学工业出版社, 2011:226-243. ELMAR H, ARNO P B, CHARLES L C. Development of Sustainable Bioprocess-Modeling and Assessment[M]. LIN D Q, YAO S J, MEI L H, trans. Beijing:Chemical Industry Press, 2011:226-243.
[20]	HARRISON R G, TODD P, RUDGE S R, et al. Bioseparations Science and Engineering[M]. 2nd ed. New York:Oxford University Press, 2015:441-507
[21]	GOTTSCHALK U. Process Scale Purification of Antibodies[M]. 2nd ed. New York:John Wiley & Sons Inc., 2017:445-463
[22]	刘国庆, 陈飞, 赵亮, 等. 表达单克隆抗体的CHO细胞无蛋白培养基的优化[J]. 高校化学工程学报, 2013, (1):96-101. LIU G Q, CHEN F, ZHAO L, et al. Optimization of protein-free culture medium for CHO cells producing monoclonal antibody[J]. Journal of Chemical Engineering of Chinese Universities, 2013, (1):96-101.
[23]	李晓璐, 范里, 赵亮, 等. 基于单纯型设计和部件搜索方法的CHO细胞无血清培养基的高通量优化[J]. 高校化学工程学报, 2014, (4):777-783. LI X L, FAN L, ZHAO L, et al. High through-put screening and optimization of serum-free media development for CHO cells using simplex lattice and elements dialogue design methods[J]. Journal of Chemical Engineering of Chinese Universities, 2014, (4):777-783.
[24]	BIBILA T A, ROBINSON D K. In pursuit of the optimal fed-batch process for monoclonal antibody production[J]. Biotechnology Progress, 1995, 11(1):1-13.
[25]	LI F, VIJAYASANKARAN N, SHEN A Y, et al. Cell culture processes for monoclonal antibody production[J]. MAbs, 2010, 2(5):466-479.
[26]	LOW D, O LEARY R, PUJAR N S. Future of antibody purification[J]. Journal of Chromatography B Analytical Technologies in the Biomedical & Life Sciences, 2007, 848(1):48-63.
[27]	BOLTON G R, MEHTA K K. The role of more than 40 years of improvement in protein A chromatography in the growth of the therapeutic antibody industry[J]. Biotechnology Progress, 2016, 32(5):1193-1201.
[28]	MÜLLER-SPÄTH T, AUMANN L, STRÖHLEIN G, et al. Two step capture and purification of IgG2 using multicolumn countercurrent solvent gradient purification (MCSGP)[J]. Biotechnology & Bioengineering, 2010, 107(6):974-987.
[29]	ANGARITA M, MÜLLERSPÄTH T, BAUR D, et al. Twin-column CaptureSMB:a novel cyclic process for protein A affinity chromatography[J]. Journal of Chromatography A, 2015, 1389:85-95.
[30]	姚善泾, 高栋, 林东强. 一种新的生物分离方法--混合模式吸附层析[J]. 化工学报, 2007, 58(9):2169-2177. YAO S J, GAO D, LIN D Q. Novel technology in bioseparation process-mixed-mode chromatography[J]. Journal of Chemical Industry and Engineering(China), 2007, 58(9):2169-2177.
[31]	李菁, 林东强, 童红飞, 等. 疏水性电荷诱导色谱分离抗HER2单克隆抗体[J]. 化工学报, 2014, 65(10):3931-3937. LI J, LIN D Q, TONG H F, et al. Separation and purification of antiHER2 monoclonal antibody with hydrophobic charge-induction chromatography[J]. CIESC Journal, 2014, 65(10):3931-3937.
[32]	TONG H F, LIN D Q, CHU W N, et al. Multimodal charge-induction chromatography for antibody purification[J]. Journal of Chromatography A, 2015, 1429:258-264.
[33]	卢慧丽, 林东强, 姚善泾. 亲和仿生层析及在抗体纯化中的应用[J]. 化工学报, 2016, 67(9):3523-3535. LU H L, LIN D Q, YAO S J. Affinity biomimetic chromatography and its applications for antibody purification[J]. CIESC Journal, 2016, 67(9):3523-3535.

单抗制备的过程模拟和经济性分析

Process simulation and economic evaluation of monoclonal antibody production

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵亚欣, 张雪芹, 王荣柱, 孙国, 姚善泾, 林东强. 流穿模式离子交换层析去除单抗聚集体[J]. 化工学报, 2023, 74(9): 3879-3887.
[2]	陈耀明,许锋,罗雄麟. 基于相对增益和优先级的化工过程协调优化裕量设计[J]. 化工学报, 2022, 73(3): 1280-1290.
[3]	刘立, 蒋鹏, 王伟, 张同桓, 穆立文, 陆小华, 朱家华. 基于过程模拟和随机森林模型的生物质制氢过程因素分析与预测[J]. 化工学报, 2022, 73(11): 5230-5239.
[4]	刘潜, 张香兰, 李志平, 栗卓琦, 喻红. 油酚分离过程离子液体萃取溶剂的多尺度筛选[J]. 化工学报, 2022, 73(11): 5011-5024.
[5]	王峥, 许锋, 罗雄麟. 乙炔加氢串联反应器全周期乙炔转化率最优分配研究[J]. 化工学报, 2022, 73(10): 4551-4564.
[6]	黄子轩, 陈欢, 李海, 王明龙, 陈光进, 刘蓓. ZIF-8浆液中试分离CO₂/N₂过程模拟及能耗分析[J]. 化工学报, 2022, 73(1): 322-331.
[7]	方远鑫, 肖武, 姜晓滨, 李祥村, 贺高红, 吴雪梅. 膜分离耦合CO₂电催化加氢制甲酸工艺的设计及模拟[J]. 化工学报, 2021, 72(9): 4740-4749.
[8]	宋振兴, 崔现宝, 张缨, 张雪梅, 何杰, 冯天扬, 王纪孝. 混合离子液体催化反应精馏合成乙酸正己酯[J]. 化工学报, 2021, 72(8): 4155-4165.
[9]	曹健, 冯新, 吉晓燕, 陆小华. 基于混合工质的多级蒸发ORC理论极限性能研究[J]. 化工学报, 2021, 72(7): 3780-3787.
[10]	肖永厚, 肖红岩, 李本源, 秦剑亮, 邱爽, 贺高红. 基于Aspen Adsorption的氦气/甲烷吸附分离过程模拟优化[J]. 化工学报, 2019, 70(7): 2556-2563.
[11]	卢慧丽, 林东强, 姚善泾. 抗体药物分离纯化中的层析技术及进展[J]. 化工学报, 2018, 69(1): 341-351.
[12]	卢绍文, 丁进良, 刘琳琳. 竖炉焙烧过程METSIM动态模拟[J]. 化工学报, 2015, 66(1): 244-250.
[13]	李菁, 林东强, 童红飞, 姚善泾, 叶帅东, 崔加友. 疏水性电荷诱导色谱分离抗HER2单克隆抗体[J]. 化工学报, 2014, 65(10): 3931-3937.
[14]	谢志平, 孙登琼, 秦亚楠, 任日菊, 龚俊波. 果糖结晶过程优化[J]. 化工学报, 2014, 65(1): 251-257.
[15]	诸林，张政，范峻铭. 基于化学链制氧的煤气化集成系统工艺参数分析[J]. 化工进展, 2014, 33(08): 1997-2003.